



Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi-110 033
Telefax : +91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909

insecticides
(INDIA) LIMITED

Ref: IIL/SE/2025/1211/01

Date: November 12, 2025

The Manager

Listing Compliance Department BSE Limited (Through BSE Listing Centre)	Listing Compliance Department National Stock Exchange of India Limited (Through NEAPS)
Scrip Code: 532851	Symbol: INSECTICID

Dear Sir/Madam,

Re: Outcome of the Board Meeting

This has reference to our letter no. IIL/SE/2025/2609/01 dated September 26, 2025.

The Board of Directors of the Insecticides (India) Limited/the Company ("Board") at their meeting held today i.e November 12, 2025, *inter alia* transacted the following business:

1. Considered and approved the Un-audited Standalone and Consolidated Financial Results of the Company, for the Quarter and half year ended September 30, 2025 along with Limited Review Report of M/s S S Kothari Mehta & Co., LLP and M/s Devesh Parekh & Co., Joint Statutory Auditors of the Company on the Financial Statements. The Financial Results were reviewed and recommended by the Audit Committee. Accordingly, we enclosed the following as Annexure I:
 - Un-audited Standalone and Consolidated Financial Results for the Quarter and half year ended on September 30, 2025.
 - Limited Review Report of the Statutory Auditor(s) on the Un-audited Standalone and Consolidated Financial Results for the Quarter and half ended on September 30, 2025.

A copy of the said results together with the Limited Review report are also being made available on the website of the Company at www.insecticidesindia.com.

2. On the recommendation of Nomination Remuneration and Ethics Committee, the Board of Directors approved the appointment of Mr. Devendra Kumar Ray as a Chief Operating Officer (COO) of the Company w.e.f November 12, 2025.

Brief profile and other details required under regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed as Annexure II.



Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi-110 033
Telefax : +91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



insecticides
(INDIA) LIMITED

The Board meeting commenced at 11:30 AM (IST) and concluded at 01:00 PM (IST)

You are requested to kindly take on records.

Thanking You,

For Insecticides India Limited

(Sandeep Kumar)

Company Secretary & CCO

Encl: As above

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ In Lacs, except EPS)

Sl No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2025 (Unaudited)	30-06-2025 (Unaudited)	30-09-2024 (Unaudited)	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)	31-03-2025 (Audited)
I	Revenue from operations	64,124.89	69,137.24	62,720.83	1,33,262.13	1,28,389.36	2,00,226.58
II	Other Income	267.44	374.51	154.24	641.95	408.12	722.58
III	Total Income (I+II)	64,392.33	69,511.75	62,875.07	1,33,904.08	1,28,797.48	2,00,949.16
IV	Expenses						
	(a) Cost of materials consumed	36,791.02	38,763.70	44,933.47	75,554.72	78,845.91	1,35,514.02
	(b) Purchase of Stock-in-Trade	4,854.87	2,949.09	2,098.48	7,803.96	4,196.61	7,511.27
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,122.25	7,407.65	(4,136.82)	8,529.90	7,454.44	(6,389.16)
	(d) Employee benefits expense	4,694.29	4,105.82	3,826.09	8,800.11	7,689.27	13,715.70
	(e) Finance costs	407.57	364.98	167.70	772.55	330.17	672.32
	(f) Depreciation and amortization expense	927.07	727.76	723.14	1,654.83	1,436.15	2,904.75
	(g) Other expenses	8,176.04	7,507.92	7,014.58	15,683.96	14,035.16	27,991.77
	Total expenses	56,973.11	61,826.92	54,626.64	1,18,800.03	1,13,987.71	1,81,920.67
V	Profit before tax (III-IV)	7,419.22	7,684.83	8,248.43	15,104.05	14,809.77	19,028.49
VI	Tax Expense						
	(1) Current Tax	1,900.71	1,839.48	2,086.74	3,740.19	3,808.13	5,539.15
	(2) Deferred Tax	(12.51)	115.30	1.35	102.79	(72.29)	(487.22)
	Total Tax Expense	1,888.20	1,954.78	2,088.09	3,842.98	3,735.84	5,051.93
VII	Profit / (loss) for the period/year (V-VI)	5,531.02	5,730.05	6,160.34	11,261.07	11,073.93	13,976.56
VIII	Other comprehensive income						
A	Items that will not be reclassified to profit or loss						
	(i) Changes in fair value of FVTOCI equity instruments	215.40	27.09	246.49	242.49	28.12	(30.71)
	(ii) Remeasurement of net defined benefit plans	(35.00)	(35.00)	(1.25)	(70.00)	(2.50)	(139.52)
	(iii) Income tax relating to these items	(41.37)	2.50	(57.11)	(38.87)	(5.92)	42.26
	Other comprehensive income for the period/year (net of tax)	139.03	(5.41)	188.13	133.62	19.70	(127.97)
IX	Total comprehensive income for the period/year (VII+VIII)	5,670.05	5,724.64	6,348.47	11,394.69	11,093.63	13,848.59
	Paid up equity share capital (Face value ₹ 10/- each)	2,909.78	2,909.78	2,959.78	2,909.78	2,959.78	2,909.78
	Other Equity	-	-	-	-	-	1,05,269.25
	Earnings per share (of ₹ 10 each) (not annualised):						
	(a) Basic	19.01	19.69	20.81	38.70	37.41	47.61
	(b) Diluted	19.01	19.69	20.81	38.70	37.41	47.61
	(Note: EPS for respective quarters are not annualized)						

Notes:

- The above Unaudited Standalone Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025. The Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com.
- The above Unaudited Standalone financial results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- The Company is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
- The Board of Directors of Insecticides (India) Limited in its meeting held on August 09, 2024 had approved the dissolution/ liquidation of Its wholly owned subsidiary IIL Overseas DMCC, Dubai. IIL Overseas DMCC has filled the windup / dissolution with DMCCA (Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority) and dissolution is approved vide its letter dated September 19, 2025.

For and on behalf of the Board of Directors
Insecticides (India) Limited



Rajesh Kumar Aggarwal
Managing Director

Place: Delhi

Date: November 12, 2025

DIN : 00576872

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED STANDALONE ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2025

(₹ In Lacs)

S. No	Particulars	As at 30-09-2025 (Unaudited)	As at 31-03-2025 (Audited)
ASSETS			
(1)	Non-current assets		
(a)	Property, plant and equipment	31,970.00	22,981.29
(b)	Capital work-in-progress	8,124.98	15,599.24
(c)	Investment properties	102.27	104.67
(d)	Right-of-use assets	4,112.48	3,904.01
(e)	Intangible assets	867.21	852.75
(f)	Intangible assets under development	978.54	498.54
(g)	Investment in subsidiaries and jointly controlled entity	1,819.27	1,823.56
(h)	Financial assets		
(i)	Investments	1,064.67	822.18
(ii)	Other financial assets	406.55	267.32
(i)	Income tax assets (net)	110.09	132.72
(j)	Other non-current assets	971.84	604.65
	Total non-current assets	50,527.90	47,590.93
(2)	Current assets		
(a)	Inventories	72,042.09	88,268.01
(b)	Financial assets		
(i)	Trade receivables	64,933.82	38,567.91
(ii)	Cash and cash equivalents	2,675.47	5,538.01
(iii)	Bank balances other than (ii) above	16.29	118.11
(iv)	Loans	36.36	25.01
(v)	Other financial assets	959.55	851.47
(c)	Other current assets	6,119.02	7,800.52
	Total current assets	1,46,782.60	1,41,169.04
	Total assets	1,97,310.50	1,88,759.97
EQUITY AND LIABILITIES			
EQUITY			
(a)	Equity share capital	2,909.78	2,909.78
(b)	Other equity	1,16,663.94	1,05,269.25
	Total equity	1,19,573.72	1,08,179.03
LIABILITIES			
(1)	Non-current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	2,162.73	2,347.24
(ii)	Lease liabilities	452.70	264.60
(b)	Provisions	544.60	544.60
(c)	Deferred tax liabilities (net)	628.30	486.63
	Total non-current liabilities	3,788.33	3,643.07
(2)	Current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	21,288.31	7,551.74
(ii)	Lease liabilities	267.01	239.54
(iii)	Trade Payables		
(A)	total outstanding due of micro enterprises and small enterprises; and	5,940.46	2,250.29
(B)	total outstanding dues of creditors other than micro enterprises and small enterprises.	34,993.34	47,777.29
(iv)	Other financial liabilities	6,312.50	4,699.45
(b)	Other current liabilities	3,741.20	13,055.91
(c)	Provisions	713.60	483.59
(d)	Current tax liabilities (net)	692.03	880.06
	Total current liabilities	73,948.45	76,937.87
	Total equity and liabilities	1,97,310.50	1,88,759.97

For and on behalf of the Board of Directors

Insecticides (India) Limited



Rajesh Kumar Aggarwal

Managing Director

DIN : 00576872

Place: Delhi

Date: November 12, 2025

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;

Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STANDALONE UNAUDITED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ In lacs)

Particulars	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)
(A) Cash Flow From Operating Activities		
Profit before tax	15,104.05	14,809.77
Adjustment on account of		
- Depreciation	1,654.83	1,436.15
- (Profit)/ Loss on sale of property, plant & equipment	(20.72)	(28.94)
- Net gain on lease modification	(1.56)	-
- Interest income	(9.46)	(138.66)
- Dividend income	-	-
- Interest expenses	772.55	330.17
- Bad debts written off	0.30	20.36
- Loss Allowance on Advances	-	-
- Impairment expenses on investment	-	-
- Provision for impairment of trade receivables	203.25	199.91
- Derivative (gain) / loss	(447.94)	1.44
- Unrealised exchange differences	81.86	(153.75)
Operating Profit Before Working Capital Changes	17,337.16	16,476.45
Adjustments for		
- (Increase)/Decrease in security deposits	(37.65)	(54.29)
- (Increase)/Decrease in inventories	16,225.92	17,252.06
- (Increase)/Decrease in trade receivables	(26,376.53)	(23,790.44)
- (Increase)/Decrease in loans	(11.35)	(21.06)
- (Increase)/Decrease in other financial assets	(6.64)	(561.35)
- (Increase)/Decrease in other current assets	1,691.00	(1,429.15)
- Increase/(Decrease) in provisions	160.00	122.50
- Increase/(Decrease) in trade payables	(9,296.14)	8,316.79
- Increase/(Decrease) in other financial liabilities	2,011.63	2,195.58
- Increase/(Decrease) in other current liabilities	(9,314.70)	(10,523.48)
Cash generated from operations	(7,617.30)	7,983.61
Less: Income tax paid	(3,905.58)	(2,056.47)
Net cash flow (used in) / from operating activities (A)	(11,522.88)	5,927.14
(B) Cash Flow From Investing Activities		
- Purchase of property, plant and equipment and intangible assets, capital-work-in-progress and intangible assets under development	(4,061.06)	(1,824.38)
- Proceeds from sale of property plant and equipment	92.39	102.16
- Interest received	9.46	138.66
- Proceeds from / (investment in) bank deposits (net)	0.24	(121.76)
- Dividends received	19.33	18.68
- Investment in equity shares of subsidiary company	4.29	(200.00)
Net cash flow (used in) / from Investing Activities (B)	(3,935.35)	(1,886.64)
(C) Cash Flow From Financing Activities		
- Repayment due to Buyback of equity shares including premium, expenses & taxes	-	-
- Repayment of non-current borrowings	(719.15)	(711.72)
- Proceeds from non-current borrowings	462.22	555.50
- Proceeds/(Repayment) from/of current borrowings	13,736.57	(2,053.96)
- Payment of lease liabilities	(135.86)	(113.19)
- Interest paid	(748.09)	(343.33)
- Dividend paid (Final & Interim)	-	(591.96)
Net cash flow (used in) / from financing activities (C)	12,595.69	(3,258.66)
Net increase/ (decrease) in Cash and Cash Equivalents (A+B+C)	(2,862.54)	781.84
Cash and Cash Equivalents at the beginning of the year	5,538.01	6,105.27
Cash and Cash Equivalents at the end of the year	2,675.47	6,887.11

For and on behalf of the Board of Directors
Insecticides (India) Limited



Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Place: Delhi

Date: November 12, 2025

S S KOTHARI MEHTA & CO. LLP

Chartered Accountants

Plot No. 68, Okhla Industrial Area, Phase-III

New Delhi - 110020

DEVESH PAREKH & CO.

Chartered Accountants

675, Aggarwal Cyber Plaza-2,

Netaji Subhash Place, Pitampura, Delhi-110034

Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Insecticides (India) Limited Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended**To****The Board of Directors****Insecticides (India) Limited****Delhi****Review Report on the Unaudited Standalone Financial Results**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Insecticides (India) Limited** (the "Company") for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This statement which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting", prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with the applicable Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S S Kothari Mehta & Co. LLP

Chartered Accountants

Firm's registration number: 000756N/ N500441

**Vijay Kumar**

Partner

Membership number: 092671

UDIN: 25092671BM0F1X7038

Place: Delhi

Date: 12th November, 2025**For Devesh Parekh & Co.**

Chartered Accountants

Firm's registration number: 013338N

**Meenakshi**

Partner

Membership number: 527873

UDIN: 25527873BNUIDA1242

Place: Delhi

Date: 12th November, 2025

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;
Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ In Lacs, except EPS)

Sl No.	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2025 (Unaudited)	30-06-2025 (Unaudited)	30-09-2024 (Unaudited)	30-09-2025 (Unaudited)	30-09-2024 (Unaudited)	31-03-2025 (Audited)
I	Revenue from operations	63,770.09	69,113.31	62,663.92	1,32,883.40	1,28,332.45	1,99,994.96
II	Other Income	250.87	370.57	150.48	621.44	398.51	699.55
III	Total Income (I+II)	64,020.96	69,483.88	62,814.40	1,33,504.84	1,28,730.96	2,00,694.51
IV	Expenses						
	(a) Cost of materials consumed	36,302.96	37,287.76	44,204.17	73,590.72	78,603.20	1,34,837.66
	(b) Purchase of Stock-in-Trade	5,784.40	4,510.41	2,704.34	10,294.81	4,196.61	7,511.27
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(289.16)	7,150.09	(4,127.11)	6,860.93	7,504.30	(6,436.78)
	(d) Employee benefits expense	4,777.36	4,152.52	3,860.54	8,929.88	7,758.47	13,870.97
	(e) Finance costs	415.53	372.26	168.54	787.79	331.75	686.45
	(f) Depreciation and amortization expense	932.99	731.28	725.81	1,664.27	1,440.19	2,915.34
	(g) Other expenses	8,246.75	7,554.02	7,050.12	15,800.77	14,084.86	28,090.11
	Total expenses	56,170.83	61,758.34	54,586.41	1,17,929.17	1,13,919.38	1,81,475.02
V	Profit / (loss) before tax and share of net profit of investment accounted for using equity method (III-IV)	7,850.13	7,725.54	8,227.99	15,575.67	14,811.58	19,219.49
VI	Share of net profit of jointly controlled entity accounted for using the equity method	35.58	19.81	17.07	55.39	34.90	57.45
VII	Profit / (loss) Before Tax (V+VI)	7,885.71	7,745.35	8,245.06	15,631.06	14,846.48	19,276.94
VIII	Tax Expense						
	(1) Current Tax	1,980.09	1,871.59	2,096.37	3,851.68	3,826.52	5,591.47
	(2) Deferred Tax	(5.13)	63.22	9.59	58.09	(56.32)	(516.39)
	Total Tax Expense	1,974.96	1,934.81	2,105.96	3,909.77	3,770.20	5,075.08
IX	Profit / (loss) for the period/year (VII-VIII)	5,910.75	5,810.54	6,139.10	11,721.29	11,076.28	14,201.86
X	Other comprehensive income						
A	Items that will not be reclassified to profit or loss						
	(i) Changes in fair value of FVTOCI equity instruments	215.40	27.09	246.49	242.49	28.12	(30.71)
	(ii) Remeasurement of net defined benefit plans	(35.00)	(35.00)	(1.25)	(70.00)	(2.50)	(139.52)
	(iii) Share of Other comprehensive income of jointly controlled entity accounted for using equity method	0.12	0.12	(4.31)	0.24	(8.62)	(8.26)
	(iv) Income tax relating to these items	(41.40)	2.47	(56.02)	(38.93)	(3.75)	44.35
B	Items that will be reclassified to profit or loss						
	(i) Exchange differences in translating the financial statements of foreign operations	0.14	(0.14)	0.21	-	0.20	(0.03)
	Other comprehensive income for the period/year (net of tax)	139.26	(5.46)	185.12	133.80	13.45	(134.17)
XI	Total comprehensive income for the period/year (IX+X)	6,050.01	5,805.08	6,324.22	11,855.09	11,089.73	14,067.69
	Other comprehensive income attributable to Owners'	139.26	(5.46)	185.12	133.80	13.45	(134.17)
	Other comprehensive income attributable to Non Controlling Interest	-	-	-	-	-	-
	Total comprehensive income attributable to Owners'	6,050.01	5,805.08	6,324.22	11,855.09	11,089.73	14,067.69
	Total comprehensive income attributable to Non Controlling Interest	-	-	-	-	-	-
	Paid up equity share capital (Face value ₹ 10/- each)	2,909.78	2,909.78	2,959.78	2,909.78	2,959.78	2,909.78
	Other Equity	-	-	-	-	-	1,05,549.60
	Earnings per share (of ₹ 10 each) (not annualised):						
	(a) Basic	20.31	19.97	20.74	40.28	37.42	48.38
	(b) Diluted	20.31	19.97	20.74	40.28	37.42	48.38

Notes:

- The above Unaudited Consolidated Financial Results have been published in accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on November 12, 2025. The Statutory Auditors have carried out a limited review of financial results. The Limited Review Report and Quarterly Financial Results are available on the Stock Exchange website at www.bseindia.com, www.nseindia.com and on the Company's website www.insecticidesindia.com.
- The above Unaudited Consolidated Financial Results have been prepared in accordance with the Indian Accounting Standard (Ind AS), the provisions of the Companies Act, 2013 ("the Act"), as applicable and guidelines issued by the Securities and Exchange Board of India ("SEBI"). The Ind AS are prescribed under Section 133 of the Act read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and subsequent amendments thereto.
- The Group is in the business of manufacturing and distribution of Agro-Chemicals and accordingly has one business segment viz "Agro-Chemicals" comprising of Technical & Formulation.
- The Board of Directors of Insecticides (India) Limited in its meeting held on August 09, 2024 had approved the dissolution/ liquidation of Its wholly owned subsidiary IIL Overseas DMCC, Dubai. IIL Overseas DMCC has filled the windup / dissolution with DMCCA (Office of the Registrar of Companies of Dubai Multi Commodities Centre Authority) and dissolution is approved vide its letter dated September 19, 2025.
- The Board of Directors of the Company, at its meeting held on November 11, 2024, approved the acquisition of 100% equity shares of 'Kaeros Research Limited' (formerly known as Kaeros Research Private Limited) ("Target Company") from its existing shareholders through a share purchase agreement ("SPA") between the existing shareholders and the Company. Consequently, target company becomes the wholly owned subsidiary of the Group. The transaction is considered as Common control transaction as per Ind AS 103. As per guidance on accounting for common control transactions contained in Ind AS 103 "Business Combinations" the acquisition has been accounted for using the pooling of interest method. Accordingly, the consolidated financial statements of the Group have been restated with effect from April 01, 2023, by transferring all assets, liabilities and reserves of the target company, with the differential amount from the purchase consideration has been recognised in capital reserve (other equity). Therefore, the figures for the quarter and six months ended September 30, 2024 have been restated.



For and on behalf of the Board of Directors
Insecticides (India) Limited

Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;

Telefax.: 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

STATEMENT OF UNAUDITED CONSOLIDATED BALANCE SHEET AS AT SEPTEMBER 30, 2025

(₹ In lacs)

S. No	Particulars	As at 30-09-2025 (Unaudited)	As at 31-03-2025 (Audited)
ASSETS			
(1)	Non-current assets		
(a)	Property, plant and equipment	32,108.15	23,119.88
(b)	Capital work-in-progress	8,136.68	15,610.93
(c)	Investment properties	309.84	299.15
(d)	Right-of-use assets	4,133.97	3,904.01
(e)	Other Intangible assets	878.76	863.40
(f)	Intangible assets under development	978.54	498.53
(g)	Investment in jointly controlled entity	1,207.94	1,152.37
(h)	Financial assets		
(i)	Investments	1,064.67	822.18
(ii)	Other financial assets	407.63	267.60
(i)	Income tax assets (net)	110.88	152.71
(j)	Other non-current assets	974.89	617.01
	Total non-current assets	50,311.95	47,307.77
(2)	Current assets		
(a)	Inventories	74,413.15	88,624.54
(b)	Financial assets		
(i)	Investments	783.68	957.45
(ii)	Trade receivables	64,269.46	38,531.65
(iii)	Cash and cash equivalents	2,700.91	5,592.70
(iv)	Bank balances other than (iii) above	16.29	118.11
(v)	Loans	36.36	25.01
(vi)	Other financial assets	908.59	802.47
(c)	Other current assets	6,233.07	7,854.86
	Total current assets	1,49,361.51	1,42,506.79
	Total assets	1,99,673.46	1,89,814.56
EQUITY AND LIABILITIES			
EQUITY			
(a)	Equity share capital	2,909.78	2,909.78
(b)	Other equity	1,17,404.74	1,05,549.60
	Total equity	1,20,314.52	1,08,459.38
LIABILITIES			
(1)	Non-current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	2,162.72	2,347.24
(ii)	Lease liabilities	465.40	264.60
(b)	Provisions	553.22	550.26
(c)	Deferred tax liabilities (Net)	540.05	443.08
	Total non-current liabilities	3,721.39	3,605.18
(2)	Current liabilities		
(a)	Financial liabilities		
(i)	Borrowings	21,740.23	7,614.99
(ii)	Lease liabilities	276.19	239.54
(iii)	Trade Payables		
(A)	total outstanding due of micro enterprises and small enterprises; and	5,995.33	2,268.36
(B)	total outstanding dues of creditors other than micro enterprises and small enterprises.	36,041.46	48,506.08
(iv)	Other financial liabilities	6,385.41	4,692.77
(b)	Other current liabilities	3,747.19	13,064.38
(c)	Provisions	713.82	483.82
(d)	Current tax liabilities (Net)	737.92	880.06
	Total current liabilities	75,637.55	77,750.00
	Total equity and liabilities	1,99,673.46	1,89,814.56

For and on behalf of the Board of Directors
Insecticides (India) Limited



Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Place: Delhi

Date: November 12, 2025

Insecticides (India) Limited

CIN: L65991DL1996PLC083909; Regd. Office: 401-402, Lusa Tower, Azadpur Commercial Complex, Delhi - 110 033;

Telefax : 011-27679700 - 05; Website: www.insecticidesindia.com; E-mail: investor@insecticidesindia.com

CONSOLIDATED UNAUDITED STATEMENT OF CASH FLOW FOR THE HALF YEAR ENDED SEPTEMBER 30, 2025

(₹ in lacs)

Particulars	30-09-2025 (Unaudited)	30-09-2024 * (Unaudited)
(A) Cash Flow From Operating Activities		
Profit before tax	15,631.06	14,846.48
Adjustment on account of		
- Share of Net Profit of Jointly controlled entity	(55.39)	(34.90)
- Depreciation	1,664.27	1,440.19
- (Profit)/ Loss on sale of property, plant & equipment	(20.72)	(28.94)
- Net gain on lease modification	(1.56)	-
- Interest income	(9.46)	(138.66)
- Dividend income	-	-
- Interest expenses	787.79	331.75
- Bad debts written off	0.30	20.36
- Loss Allowance on Advances	-	-
- Provision for impairment of trade receivables	203.25	199.91
- Gain on investment	(6.87)	0.30
- Derivative (gain) / loss	(467.31)	(11.80)
- Liabilities written back	(2.72)	-
- Unrealised exchange differences	81.86	(153.54)
Operating Profit Before Working Capital Changes	17,804.50	16,471.15
Adjustments for		
- (Increase)/Decrease in security deposits	(38.45)	(54.30)
- (Increase)/Decrease in inventories	14,211.40	16,820.40
- (Increase)/Decrease in trade receivables	(25,300.49)	(23,664.77)
- (Increase)/Decrease in loans	(11.35)	(21.06)
- (Increase)/Decrease in other financial assets	(125.45)	(561.53)
- (Increase)/Decrease in other current assets	1,631.30	(1,499.06)
- Increase/(Decrease) in provisions	162.95	122.50
- Increase/(Decrease) in trade payables	(8,937.39)	8,902.22
- Increase/(Decrease) in other financial liabilities	1,761.70	2,163.90
- Increase/(Decrease) in other current liabilities	(9,317.18)	(10,545.70)
Cash generated from operations	(8,158.46)	8,133.75
Less: Income tax paid	(3,951.87)	(2,078.18)
Net cash flow (used in) / from operating activities (A)	(12,110.33)	6,055.57
(B) Cash Flow From Investing Activities		
- Purchase of property, plant and equipment and intangible assets, capital-work-in-progress and intangible assets under development	(4,072.20)	(1,933.00)
- Proceeds from sale of property plant and equipment	92.39	102.16
- Interest received	9.46	138.66
- Proceeds from / (investment in) bank deposits (net)	0.24	(121.76)
- Inter Corporate Loans (Given) / Received back	-	-
- Purchase of investment	-	(165.61)
- Sale of investment	200.00	-
- Dividends received	19.33	18.68
- Investment in Equity shares of subsidiary co.	-	-
Net cash flow (used in) / from Investing Activities (B)	(3,750.78)	(1,960.87)
(C) Cash Flow From Financing Activities		
- Repayment due to Buyback of equity shares including premium, expenses & taxes		
- Repayment of non-current borrowings	(719.15)	(711.72)
- Proceeds from non-current borrowings	462.22	555.50
- Proceeds/(Repayment) from/of current borrowings	14,125.25	(2,053.97)
- Payment of lease liabilities	(162.20)	(113.19)
- Interest paid	(736.80)	(344.89)
- Dividend paid (Final & Interim)	-	(591.96)
Net cash flow (used in) / from financing activities (C)	12,969.32	(3,260.23)
Net increase/ (decrease) in Cash and Cash Equivalents (A+B+C)	(2,891.79)	834.47
Cash and Cash Equivalents at the beginning of the year	5,592.70	6,128.26
Cash and Cash Equivalents at the end of the year	2,700.91	6,962.73

* Restated

For and on behalf of the Board of Directors
Insecticides (India) Limited

Rajesh Kumar Aggarwal
Managing Director
DIN : 00576872

Place: Delhi
Date: November 12, 2025

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors

Insecticides (India) Limited

Delhi

Review Report on the Unaudited Consolidated Financial Results

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Insecticides (India) Limited** ("the Parent or the Company"), and its subsidiaries (Parent Company and its subsidiaries together referred to as "the Group") and its share of net profit /(loss) after tax and total comprehensive income/ (loss) of its jointly controlled entity for the quarter ended September 30, 2025 and for the period from April 01, 2025 to September 30, 2025 ("the Statement"), attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34, "Interim Financial Reporting" ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 read with the relevant rules thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:

Parent

Insecticides (India) Limited

Subsidiary

IIL Biologicals Limited

IIL Overseas DMCC (Dubai) (Dissolved w.e.f September 19, 2025)

Kaeros Research Limited (formerly known as "Kaeros Research Private Limited")

Jointly Controlled Entity

OAT & IIL India Laboratories Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the other matters referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. Other Matters:

- a) The accompanying unaudited consolidated financial results include the unaudited financial results of two subsidiaries, which reflect total assets of Rs. 7,882.09 lacs as at September 30, 2025, total revenue of Rs. 3,914.42 Lacs and Rs. 6,556.19 Lacs, total net profit after tax of Rs. 336.21 Lacs and Rs. 446.60 lacs and total comprehensive income of Rs. 336.21 Lacs and Rs. 446.61 for the quarter ended September 30, 2025 and for the period April 01, 2025 to September 30, 2025 respectively, which have been reviewed by one of the joint auditors, individually.

The reports on the unaudited financial results of above entity have been furnished to us by the management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary, is based solely on the reports of such auditors and the procedures performed by us are as stated in paragraph 3 above.

Our conclusion on the statement is not modified in respect of the above matters.

- b) The unaudited consolidated financial results also include the Group's share of net profit of Rs 35.58 Lacs and Rs. 55.39 Lacs and total comprehensive income of Rs. 35.67 Lacs and Rs. 55.57 Lacs for the quarter ended September 30, 2025 and for the period April 01, 2025 to September 30, 2025 respectively, as considered in the unaudited consolidated financial results in respect of jointly controlled entity.

These unaudited financial results have not been reviewed by their auditors and have been approved and furnished to us by the management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of said jointly controlled entity, is based solely on such unaudited financial results.

The wholly owned foreign subsidiary of the Company, IIL Overseas DMCC (Dubai) was dissolved with effect from September 19, 2025 and has no operation for the quarter ended September 30, 2025 and for the period April 01, 2025 to September 30, 2025. (Refer note no. 4 of the statement). Therefore, the statement does not include any financial results for this subsidiary for the quarter ended September 30, 2025 and for the period April 01, 2025 to September 30, 2025.

According to the information and explanations given to us by the Management, these financial results are not material to the group.

Our conclusion on the statement is not modified in respect of the above matters.

7. We draw attention to Note no. 5 to the accompanying Statement, in respect of purchase of shares of Target Company from its existing shareholders through a share purchase agreement between the existing shareholders and the Company. This transaction has been accounted under 'the pooling of interests method' i.e. in accordance with Appendix C of IND AS 103 'Business Combination'.

In view of the above and in terms of the requirements under applicable Ind AS, the figures for the quarter ended September 30, 2024 and for the period April 01, 2024 to September 30, 2024 have been restated.

Our conclusion on the statement is not modified in respect of the above matter.

For **S S Kothari Mehta & Co. LLP**

Chartered Accountants

FRN: 000756N/ N500441

Vijay Kumar

Partner

Membership number: 092671

UDIN: 25092671BM0F1Y3609

Place: Delhi

Date: 12th November, 2025

For **Devesh Parekh & Co.**

Chartered Accountants

FRN: 013338N

Meenakshi

Partner

Membership number: 527873

UDIN: 25527873BNUIDB5010

Place: Delhi

Date: 12th November, 2025



Regd. & Corporate Office : 401-402, Lusa Tower
Azadpur Commercial Complex, Delhi - 110 033
Telefax : +91 1127679700-05 (6 Lines)
e mail : info@insecticidesindia.com
www.insecticidesindia.com
CIN : L65991DL1996PLC083909



insecticides
(INDIA) LIMITED

Annexure II

Details of appointment as required under Regulation 30 read with Para A (7) of Part A of Schedule III to the SEBI Listing Regulations and SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024

S. No.	Particulars	Description
1.	Name	Mr. Devendra Kumar Ray, Chief Operating Officer (COO)
2.	Reason for change viz. appointment, resignation, removal, death or otherwise;	Appointment
3.	Date of appointment/cessation (as applicable) & Term of appointment	November 12, 2025
4.	Brief profile (in case of appointment);	Mr. Devendra Kumar Ray is a seasoned professional with over 35 years of experience in large size chemical manufacturing & operations management, process development, technology transfer, and strategic project execution. By qualification, he has a Degree in B.Tech. Chemical Technology from HBTI, Kanpur with additional qualification of BSc Chemistry from University of Allahabad. He has successfully led end-to-end plant operations, large capital projects, and business transformation initiatives driving significant improvements in efficiency, safety, sustainability and Responsible Care across complex manufacturing environments. His core strengths include operational excellence, process safety management, sustainability leadership, ESG implementation, and people-centric governance. He has a proven track record of executing multi-crore projects within stringent timelines and safety standards, while fostering a culture of continuous improvement and innovation.

		Prior to joining Insecticides, Mr. Ray has held senior leadership positions with PI Industries Ltd., Cheminova India Ltd. (now FMC Ltd.), Neogen Chemicals Ltd, Cohizon Life Sciences Ltd. (previously Sajjan India Ltd) Atul Ltd, Searle India and Hoechst India (German MNC).
5.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable.